PT - JOURNAL ARTICLE AU - Marques, Andrew D. AU - Sherrill-Mix, Scott AU - Everett, John AU - Reddy, Shantan AU - Hokama, Pascha AU - Roche, Aoife M. AU - Hwang, Young AU - Glascock, Abigail AU - Whiteside, Samantha A. AU - Graham-Wooten, Jevon AU - Khatib, Layla A. AU - Fitzgerald, Ayannah S. AU - Moustafa, Ahmed M. AU - Bianco, Colleen AU - Rajagopal, Swetha AU - Helton, Jenna AU - Deming, Regan AU - Denu, Lidiya AU - Ahmed, Azad AU - Kitt, Eimear AU - Coffin, Susan E. AU - Newbern, Claire AU - Mell, Josh Chang AU - Planet, Paul J. AU - Badjatia, Nitika AU - Richards, Bonnie AU - Wang, Zi-Xuan AU - Cannuscio, Carolyn C. AU - Strelau, Katherine M. AU - Jaskowiak-Barr, Anne AU - Cressman, Leigh AU - Loughrey, Sean AU - Ganguly, Arupa AU - Feldman, Michael D. AU - Collman, Ronald G. AU - Rodino, Kyle G. AU - Kelly, Brendan J. AU - Bushman, Frederic D. TI - SARS-CoV-2 variants associated with vaccine breakthrough in the Delaware Valley through summer 2021 AID - 10.1101/2021.10.18.21264623 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.18.21264623 4099 - http://medrxiv.org/content/early/2021/10/20/2021.10.18.21264623.short 4100 - http://medrxiv.org/content/early/2021/10/20/2021.10.18.21264623.full AB - The severe acute respiratory coronavirus-2 (SARS-CoV-2) is the cause of the global outbreak of COVID-19. Evidence suggests that the virus is evolving to allow efficient spread through the human population, including vaccinated individuals. Here we report a study of viral variants from surveillance of the Delaware Valley, including the city of Philadelphia, and variants infecting vaccinated subjects. We sequenced and analyzed complete viral genomes from 2621 surveillance samples from March 2020 to September 2021 and compared them to genome sequences from 159 vaccine breakthroughs. In the early spring of 2020, all detected variants were of the B.1 and closely related lineages. A mixture of lineages followed, notably including B.1.243 followed by B.1.1.7 (alpha), with other lineages present at lower levels. Later isolations were dominated by B.1.617.2 (delta) and other delta lineages; delta was the exclusive variant present by the last time sampled. To investigate whether any variants appeared preferentially in vaccine breakthroughs, we devised a model based on Bayesian autoregressive moving average logistic multinomial regression to allow rigorous comparison. This revealed that B.1.617.2 (delta) showed three-fold enrichment in vaccine breakthrough cases (odds ratio of 3; 95% credible interval 0.89-11). Viral point substitutions could also be associated with vaccine breakthroughs, notably the N501Y substitution found in the alpha, beta and gamma variants (odds ratio 2.04; 95% credible interval of 1.25-3.18). This study thus provides a detailed picture of viral evolution in the Delaware Valley and a geographically matched analysis of vaccine breakthroughs; it also introduces a rigorous statistical approach to interrogating enrichment of viral variants.Importance SARS-CoV-2 vaccination is highly effective at reducing viral infection, hospitalization and death. However, vaccine breakthrough infections have been widely observed, raising the question of whether particular viral variants or viral mutations are associated with breakthrough. Here we report analysis of 2621 surveillance isolates from xsxpeople diagnosed with COVID-19 in the Delaware Valley in South Eastern Pennsylvania, allowing rigorous comparison to 159 vaccine breakthrough case specimens. Our best estimate is a three-fold enrichment for some lineages of delta among breakthroughs, and enrichment of a notable spike substitution, N501Y. We introduce statistical methods that should be widely useful for evaluating vaccine breakthroughs and other viral phenotypes.Competing Interest StatementRG Collman reports support to his lab for COVID-19 work unrelated to the current manuscript from OraSure, Inc, and ongoing collaborations with Resilient Biotics, Inc. All other authors have no competing interests to report. Funding StatementFunding was provided by a contract award from the Centers for Disease Control and Prevention (CDC BAA 200-2021-10986 and 75D30121C11102/000HCVL1-2021-55232), philanthropic donations to the Penn Center for Research on Coronaviruses and Other Emerging Pathogens, and in part by NIH grant R61/33-HL137063 and AI140442 -supplement for SARS-CoV-2. BJK is supported by NIH K23 AI 121485. Additional assistance was provided by the Penn Center for AIDS Research (P30-AI045008) and the Women's Committee of CHOP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Pennsylvania Institutional Review Board (IRB) reviewed the research protocol and deemed the limited data elements extracted with positive SARS-CoV-2 specimens to be exempt from human subject research per 45 CFR 46.104, category 4 (IRB #848605). For hospitalized subjects at the University of Pennsylvania, following informed consent (IRB protocol #823392), patients were sampled by collection of saliva, oropharyngeal and/or nasopharyngeal swabs, or endotracheal aspirates if intubated, as previously described (33). Clinical data was extracted from the electronic medical record. Further samples were collected from asymptomatic subjects detected in a screening program at the Perelman School of Medicine at the University of Pennsylvania and symptomatic subjects tested throughout the PennMedicine clinical network under IRB protocols #843565 and #848608. Human samples were collected at Children’s Hospital of Philadelphia under protocol # 21-018726 approved by the Children's Hospital of Philadelphia IRB. Human samples were collected at Thomas Jefferson University under protocol number IRB Control # 21E.441 approved by the Thomas Jefferson University IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll viral genome sequences acquired in this study have been deposited in GISAID and at NCBI under accession numbers listed in Table S1. Analysis code is available at http://github.com/sherrillmix/longitudinalLineages and will be deposited on Zenodo prior to final submission. Sequence processing software and intermediate files used in this study are available at DOI:10.5281/zenodo.5559699. A list of key reagents used in this study is in Table S8.